249 related articles for article (PubMed ID: 35853457)
21. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
[TBL] [Abstract][Full Text] [Related]
22. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
[TBL] [Abstract][Full Text] [Related]
23. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.
Bai Y; Su X
Asia Pac J Clin Oncol; 2021 Feb; 17(1):29-35. PubMed ID: 32920949
[TBL] [Abstract][Full Text] [Related]
24. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.
Gu C; Wang Y; Zhang L; Qiao L; Sun S; Shao M; Tang X; Ding P; Tang C; Cao Y; Zhou Y; Guo M; Wei R; Li N; Xiao Y; Duan J; Yang Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):11. PubMed ID: 34991674
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
26. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
Yu Z; Wei X; Liu L; Sun H; Fang T; Wang L; Li Y; Sui W; Wang K; He Y; Zhao Y; Huang W; An G; Meng F; Huang C; Yu T; Anderson KC; Cheng T; Qiu L; Hao M
EBioMedicine; 2022 Apr; 78():103950. PubMed ID: 35344764
[TBL] [Abstract][Full Text] [Related]
27. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
28. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
29. Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
Skorda A; Sklirou AD; Sakellaropoulos T; Gianniou DD; Kastritis E; Terpos E; Tsitsilonis OE; Florea BI; Overkleeft HS; Dimopoulos MA; Alexopoulos LG; Trougakos IP
J Cell Mol Med; 2019 Dec; 23(12):8010-8018. PubMed ID: 31568628
[TBL] [Abstract][Full Text] [Related]
30. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma.
Haertle L; Barrio S; Munawar U; Han S; Zhou X; Simicek M; Vogt C; Truger M; Fernandez RA; Steinhardt M; Weingart J; Snaurova R; Nerreter S; Teufel E; Garitano-Trojaola A; Da Viá M; Ruiz-Heredia Y; Rosenwald A; Bolli N; Hajek R; Raab P; Raab MS; Weinhold N; Haferlach C; Haaf T; Martinez-Lopez J; Einsele H; Rasche L; Kortüm KM
Clin Cancer Res; 2023 Jan; 29(1):279-288. PubMed ID: 36282272
[TBL] [Abstract][Full Text] [Related]
31. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
32. Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.
Sogabe K; Nakamura S; Higa Y; Miki H; Oda A; Maruhashi T; Sumitani R; Oura M; Takahashi M; Nakamura M; Maeda Y; Hara T; Yamagami H; Fujii S; Kagawa K; Ozaki S; Kurahashi K; Endo I; Aihara KI; Nakaue E; Hiasa M; Teramachi J; Harada T; Abe M
Int J Hematol; 2024 Mar; 119(3):303-315. PubMed ID: 38245883
[TBL] [Abstract][Full Text] [Related]
33. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Zhang XD; Baladandayuthapani V; Lin H; Mulligan G; Li B; Esseltine DW; Qi L; Xu J; Hunziker W; Barlogie B; Usmani SZ; Zhang Q; Crowley J; Hoering A; Shah JJ; Weber DM; Manasanch EE; Thomas SK; Li BZ; Wang HH; Zhang J; Kuiatse I; Tang JL; Wang H; He J; Yang J; Milan E; Cenci S; Ma WC; Wang ZQ; Davis RE; Yang L; Orlowski RZ
Cancer Cell; 2016 May; 29(5):639-652. PubMed ID: 27132469
[TBL] [Abstract][Full Text] [Related]
34. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
35. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
[TBL] [Abstract][Full Text] [Related]
36. The Sec61 translocon is a therapeutic vulnerability in multiple myeloma.
Domenger A; Choisy C; Baron L; Mayau V; Perthame E; Deriano L; Arnulf B; Bories JC; Dadaglio G; Demangel C
EMBO Mol Med; 2022 Mar; 14(3):e14740. PubMed ID: 35014767
[TBL] [Abstract][Full Text] [Related]
37. Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma.
Huang L; Wang Y; Bai J; Yang Y; Wang F; Feng Y; Zhang R; Li F; Zhang P; Lv N; Lei L; Hu J; He A
Cell Stress Chaperones; 2020 Mar; 25(2):357-367. PubMed ID: 32026316
[TBL] [Abstract][Full Text] [Related]
38. Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.
Zafeiropoulou K; Kalampounias G; Alexis S; Anastasopoulos D; Symeonidis A; Katsoris P
PLoS One; 2024; 19(2):e0289904. PubMed ID: 38412186
[TBL] [Abstract][Full Text] [Related]
39. Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.
Mittenberg AG; Kuzyk VO; Shabelnikov SV; Gorbach DP; Shatrova AN; Fedorova OA; Barlev NA
Cell Cycle; 2018; 17(14):1745-1756. PubMed ID: 30009671
[TBL] [Abstract][Full Text] [Related]
40. Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance.
Leonardo-Sousa C; Carvalho AN; Guedes RA; Fernandes PMP; Aniceto N; Salvador JAR; Gama MJ; Guedes RC
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]